INNOVIVA, INC. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
INNOVIVA, INC. (INVA) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $313.00 thousand for the 12-month period ending 2021-12-31, per its 10-K/A filed 2024-03-05.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2024-03-05
- INNOVIVA, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2021 was $313.00K, a 99.36% increase from fiscal 2020.
- INNOVIVA, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2020 was $157.00K, a 121.13% increase from fiscal 2019.
- INNOVIVA, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2019 was $71.00K, a 5.33% decline from fiscal 2018.
- INNOVIVA, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2018 was $75.00K.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2021-12-31 | $313.00K 10-K/A · filed 2024-03-05 |
| 2020-12-31 | $157.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | $71.00K 10-K/A · filed 2022-03-17 |
| 2018-12-31 | $75.00K 10-K · filed 2021-02-25 |
| 2014-12-31 | $42.65M 10-K · filed 2017-02-28 |
| 2013-12-31 | $565.00K 10-K · filed 2016-02-24 |
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 |
| 2011-12-31 | $0.00 10-K · filed 2014-03-03 |
| 2009-12-31 | $100.00K 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |